Evidence map›Paper›PMID 41646440›Full record

ArticleFrontiers in oncology2026

Ultra-late triple metastasis to the breast, lung, and brain 25 years after nephrectomy for clear cell renal cell carcinoma: a case report and literature review.

Sujian Xiao, Xinyu Wang, Xiaoling Deng, Xin Huang, Chuance Du, Huozhong Yuan, Yanyan Li, Qiliang Zhai

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sujian Xiao *Department of Breast, The Affiliated Ganzhou Hospital, Jiangxi Medical College, Nanchang University, Jiangxi, China.
Xinyu Wang *Department of Urology, The Affiliated Ganzhou Hospital, Jiangxi Medical College, Nanchang University, Jiangxi, China.
Xiaoling Deng *Infectious Disease Department, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Xin HuangDepartment of Urology, The Affiliated Ganzhou Hospital, Jiangxi Medical College, Nanchang University, Jiangxi, China.
Chuance DuDepartment of Urology, The Affiliated Ganzhou Hospital, Jiangxi Medical College, Nanchang University, Jiangxi, China.
Huozhong YuanDepartment of Breast, The Affiliated Ganzhou Hospital, Jiangxi Medical College, Nanchang University, Jiangxi, China.
Yanyan LiPathology Department, The Affiliated Ganzhou Hospital, Jiangxi Medical College, Nanchang University, Jiangxi, China.
Qiliang ZhaiDepartment of Urology, The Affiliated Ganzhou Hospital, Jiangxi Medical College, Nanchang University, Jiangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Clear cell renal cell carcinoma (ccRCC) most commonly metastasizes to the lungs, lymph nodes, bones, and liver. Metastasis to the breast is exceptionally rare, representing less than 0.5% of cases. Herein, we report an unprecedented case of triple metastasis with the longest recorded latency period. Case presentation: An 86-year-old female presented with a painless left breast mass 25 years after undergoing radical nephrectomy for ccRCC. Multi-modality imaging (mammography, ultrasound, MRI) revealed a suspicious breast lesion. Subsequent chest CT and PET-CT identified synchronous metastatic nodules in the lungs and brain. Histopathological examination of the resected breast mass confirmed metastatic carcinoma. The diagnosis of ccRCC metastasis was substantiated by an immunohistochemical profile positive for PAX8, CAIX, and CD10, while negative for estrogen receptor, progesterone receptor, and HER2. Conclusion: This case highlights breast metastasis as a rare but critical differential diagnosis in patients with a history of ccRCC, even decades after initial treatment. It underscores the necessity of lifelong follow-up for ccRCC survivors and demonstrates the integral role of imaging and pathological confirmation in guiding clinical diagnosis. Furthermore, the remarkable 25-year latency period challenges existing surveillance paradigms and provides a compelling rationale for the use of combined immunotherapy and targeted agents in managing ultra-late, multi-metastatic recurrences.

Indexed as

breast metastasiscase reportclear cell renal cell carcinomaimmunotherapylifelong follow-upultra-late recurrence

Identifiers

PMID41646440
PMCPMC12867817

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.